Vitiligo is generally a progressive condition, but the pace and pattern of spread vary enormously from person to person. Some people develop a few small patches that remain unchanged for years. Others experience ongoing cycles of new patches appearing throughout their lives. The type of vitiligo you have is the single biggest factor in predicting whether it will keep spreading.
How the Two Types Progress Differently
Non-segmental vitiligo, which accounts for the large majority of cases, tends to spread slowly and unpredictably. New patches can develop off and on throughout a person’s life, and the condition is prone to reactivation even after long stretches of stability. Research published in the Indian Dermatology Online Journal found no duration of inactivity after which the risk of new patches meaningfully decreased. In other words, someone with non-segmental vitiligo who has been stable for five years faces a similar risk of flare-up as someone stable for two years.
Segmental vitiligo behaves very differently. It typically causes rapid color loss on one side of the body, then stops. After about 6 to 12 months, color loss usually stabilizes, and most people with this type never develop new patches. Once segmental vitiligo has been stable for at least two years, it is roughly five times less likely to reactivate compared to cases that have been stable for a shorter period.
Signs That Vitiligo Is Actively Spreading
Dermatologists look for three visual markers that signal active disease. The first is a “confetti-like” pattern of tiny white spots clustered around existing patches. The second is a trichrome sign, where the border of a patch shows three distinct shades (white, tan, and normal skin) rather than a sharp edge, suggesting the depigmentation is gradually expanding outward. The third is the Koebner phenomenon, where new white patches appear at sites of skin injury.
A study in JAMA Dermatology found that patients with multiple active markers at once tend to need more intensive treatment, because the presence of several signs together indicates the disease is behaving more aggressively. If you notice new spots appearing in areas where your skin was recently scratched, sunburned, or irritated, that’s a strong signal of active progression.
What Triggers Spread
The Koebner phenomenon is one of the most well-documented triggers. Burns, friction, insect bites, surgical cuts, and even allergic skin reactions can cause new depigmented patches to form at the site of injury. Skin trauma appears to activate the immune response that destroys pigment-producing cells, essentially giving the disease a new foothold.
Several factors are statistically linked to more aggressive progression. A large study found that people who experience the Koebner phenomenon are more likely to have active, spreading disease, patches covering more than 2% of their body, and coexisting autoimmune conditions. Having another autoimmune disorder, particularly thyroid disease like Hashimoto’s thyroiditis or Graves’ disease, correlates with broader involvement. Female sex, a family history of autoimmunity, and longer disease duration are all associated with higher rates of thyroid-related antibodies, which may reflect a more active autoimmune profile overall.
Age of Onset Matters
Children diagnosed with vitiligo at very young ages tend to have more extensive and progressive disease. A study of 208 children found that early-onset cases had higher percentages of body surface area involved and faster rates of spread over an average follow-up of about two years, compared to children diagnosed later in childhood. Importantly, the two groups did not differ in their likelihood of repigmentation or in vitiligo type, suggesting that early onset specifically drives more aggressive spread rather than a fundamentally different form of the disease.
Can Vitiligo Stabilize on Its Own?
It can, and it does for a meaningful number of people. About one in five people with vitiligo experience some degree of spontaneous repigmentation, meaning color returns to patches without any treatment. Complete repigmentation without intervention is far rarer, occurring in roughly 3.6% of cases. More commonly, partial color return happens in scattered areas while other patches remain stable or continue to grow.
Clinically, vitiligo is considered “stable” when no new patches have appeared and no existing patches have expanded for at least 12 months. This definition matters most when doctors are considering surgical options like skin grafting or cell-based repigmentation procedures, which work best on patches that have stopped changing.
How Treatment Affects Progression
Treatments for vitiligo now go beyond cosmetic coverage. A topical cream that works by blocking specific immune signaling pathways (a JAK inhibitor called ruxolitinib) became the first approved repigmentation treatment for vitiligo. In pooled data from two large clinical trials, about half of patients using the cream achieved meaningful facial repigmentation within one year. Notably, results were similar whether patients had stable or actively progressive disease at the start of treatment, with response rates of roughly 49% and 53% respectively.
These results suggest that active spread does not make treatment futile. People with progressive vitiligo responded just as well as those whose disease had already stabilized, and outcomes were consistent regardless of how long someone had lived with the condition, whether under 10 years or over 20.
Tracking Your Own Progression
Doctors measure vitiligo severity using the Vitiligo Area Scoring Index, which combines the percentage of body surface affected with the degree of depigmentation in each area. You don’t need to calculate a formal score at home, but photographing your patches in consistent lighting every few months gives you and your dermatologist a reliable record of change. Pay attention to patch borders: sharp, stable edges suggest inactive disease, while fuzzy or tri-colored borders suggest the patches may be expanding. New tiny spots near existing patches are the clearest sign that the disease is on the move.